Argenx price target raised to $925 from $860 at RBC Capital

RBC Capital raised the firm’s price target on Argenx (ARGX) to $925 from $860 and keeps an Outperform rating on the shares. While the stock has performed strongly over the last few months, the firm sees upside from here, with Argenx having both commercial execution and a pipeline, the analyst tells investors in a research note. There aren’s many Biotech companies that will likely add about $2B to their top line next year and materially expand margins, the firm added.